Abstract
Mitochondrial dysfunction is thought to be a critical pathway in the development and progression of kidney diseases, but optimal methods to assess kidney mitochondrial dysfunction are not well known. Saeki and colleagues use positron emission tomography imaging with a novel probe, 2-tert-butyl-4-chloro-5-[6-(4-18F-fluorobutoxy)-pyridin-3-ylmethoxy]-2H-pyridazin-3-one (18F-BCPP-BF), to visualize and assess kidney mitochondrial status. The authors demonstrate that reduced uptake of 18F-BCPP-BF, as assessed by positron emission tomography imaging, corresponds to reduced functioning mitochondria in 3 separate animal models of kidney diseases.
Original language | English (US) |
---|---|
Pages (from-to) | 51-53 |
Number of pages | 3 |
Journal | Kidney international |
Volume | 98 |
Issue number | 1 |
DOIs |
|
State | Published - Jul 2020 |
Funding
AS is supported by National Institutes of Health grant K23DK120811 , the Dixon Translational Research Grants Initiative at Northwestern Medicine and the Northwestern University Clinical and Translational Sciences Institute ( UL1TR001422 ), and core resources from the George M. O’Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. PVP is supported in part by R01DK106557.
ASJC Scopus subject areas
- Nephrology